Page last updated: 2024-08-23

daunorubicin and tipifarnib

daunorubicin has been researched along with tipifarnib in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brandwein, JM; Gupta, V; Howson-Jan, K; Leber, BF; MacAlpine, K; Minden, MD; Moore, M; Schimmer, AD; Schuh, AC; Wright, J; Yee, KW	1
Karp, J	1
Christos, PJ; Feldman, EJ; Gergis, U; Mayer, S; Ritchie, EK; Roboz, GJ; Scandura, JM; Wissa, U	1

Trials

1 trial(s) available for daunorubicin and tipifarnib

Article	Year
A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over. Leukemia, 2009, Volume: 23, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug-Related Side Effects and Adverse Reactions; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Quinolones; Remission Induction	2009

Article

Year

A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.

Leukemia, 2009, Volume: 23, Issue:4

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug-Related Side Effects and Adverse Reactions; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Quinolones; Remission Induction

2009

Other Studies

2 other study(ies) available for daunorubicin and tipifarnib

Article	Year
Future research directions for the treatment of AML. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11 Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin	2008
Are low-intensity induction strategies better for older patients with acute myeloid leukemia? Leukemia research, 2012, Volume: 36, Issue:4 Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome	2012

Article

Year

Future research directions for the treatment of AML.

Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11

Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin

2008

Are low-intensity induction strategies better for older patients with acute myeloid leukemia?

Leukemia research, 2012, Volume: 36, Issue:4

Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome

2012